Exhibit 99.2 Q3 2025 Earnings Supplement November 2025 Disclaimer 1 Repay Holdings Corporation ("REPAY" or the "Company") is required to file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission ("SEC") Such filings, which you may obtain for free at the SEC's website at http://www.sec.gov, discuss some of the important risk factors that may affect REPAY's business, results of operations and financial condition. Forward-Looking Statements T ...

Financial Highlights - FibroGen completed the sale of FibroGen China to AstraZeneca for approximately $220 million[3, 50] - The sale included an enterprise value of $85 million and approximately $135 million of FibroGen net cash held in China[50] - The company successfully repaid its term loan to Morgan Stanley Tactical Value[3, 50] - FibroGen extended its cash runway into 2028[3, 50] FG-3246 and FG-3180 Program (Prostate Cancer) - Phase 2 monotherapy trial of FG-3246 and FG-3180 in mCRPC (post-ARPI / pre-chemo setting) has been initiated, with interim results expected in 2H 2026[3, 17, 18] - In a Phase 1 monotherapy study, FG-3246 showed a median rPFS of 8.7 months and a PSA decline of >50% in approximately 36% of patients[15] - In a Phase 1b combination study with enzalutamide, FG-3246 showed a preliminary estimate of median rPFS of 10.2 months and PSA declines in 71% of evaluable patients[15] - Topline results from an investigator-sponsored trial (IST) of FG-3246 in combination with enzalutamide in mCRPC are expected in 1Q 2026[3, 15] Roxadustat (Anemia of LR-MDS) - Roxadustat is being developed as a late-stage development opportunity for anemia due to LR-MDS and high red blood cell transfusion burden[3, 36] - In a post-hoc analysis of the MATTERHORN Phase 3 trial, roxadustat showed promising transfusion independence (TI) benefits compared to placebo in patients with high transfusion burden, with 36% achieving 8-week RBC-TI within 28 weeks compared to 7% for placebo[37, 38] - Phase 3 protocol submission is anticipated in 4Q 2025 for roxadustat in anemia of LR-MDS, with potential Phase 3 initiation in 2026[3, 45]

Theravance Biopharma Third Quarter 2025 Financial Results and Business Update November 10, 2025 THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third-party trademarks used herein are the property of their respective owners. © 2025 Theravance Biopharma. All rights reserved. Forward Looking Statements Examples of such statements include statement ...

Company Overview - Health In Tech (HIT) is transforming healthcare through digital innovation, focusing on the self-funded healthcare insurance market for businesses [6, 7] - The company's AI-driven platform streamlines the design and purchase of healthcare plans, integrating brokers, employers, TPAs, carriers, hospitals, and clinics [7] - HITChain, a blockchain-enabled healthcare insurance claims processing platform, is being developed to target the $4.5 trillion U.S healthcare market and over $300 billion in annual claims administration costs [26, 27] Technology and Efficiency - HIT's integrated AI underwriting reduces underwriting time by 80%-90%, from 12 days/3 months to 2 minutes/2 weeks for small/large employers respectively [9, 10, 14, 15] - The eDIYBS platform empowers brokers to customize self-funded healthcare plans and generate bindable healthcare insurance quotes promptly [8, 13] - HI Performance National Network offers Medicare-based reimbursement pricing across 50 states, with 7,380 hospitals and 1,153,684 provider locations as of September 30, 2025 [16] Market and Financial Performance - Small businesses, employing 59 million people, contribute 44% ($12.7 trillion) of the GDP, representing a significant market opportunity [20, 21] - The U.S healthcare insurance market is a massive $1.7 trillion market primed for disruption [23, 25] - For the first nine months of 2025, revenue reached $25.8 million, a 132% increase compared to the full year 2024 revenue of $19.5 million [31] - Adjusted EBITDA for the first nine months of 2025 was $3.8 million, a 167% increase compared to the full year 2024 total of $2.3 million [31] - Cash and cash equivalents increased from $1.7 million in September 2024 to $8.0 million in September 2025 [44]

Q3 2025 Financial Performance - Non-GAAP Revenue increased by 21% to $492 million[5, 19] - Adjusted EBITDA declined by 17% to $23.6 million[5, 19] - Non-GAAP EPS decreased by 54% to $0.06[5, 20] - Consumer Services revenue was down 10% to $88.3 million[21] - B2B Services revenue increased by 32% to $364.2 million[21] - Money Movement revenue decreased by 6% to $29.8 million[21] Key Metrics - Active accounts increased by 1%[6, 28] - B2B Services active accounts increased 13% offsetting a 9% decline in Consumer Services active accounts[31] - Gross Dollar Volume (GDV) increased by 18%[29] 2025 Guidance - Projected Non-GAAP Revenue is expected to be between $2 billion and $2.1 billion, representing a 20% growth at the mid-point[61, 62] - Projected Adjusted EBITDA is expected to be between $165 million and $175 million[61] - Projected Non-GAAP EPS is expected to be between $1.31 and $1.44[61]

Financial Performance - Revenue for Q3 2025 reached $1498 million, a 204% increase year-over-year[15] - Adjusted EBITDA for Q3 2025 was $196 million, up 161% year-over-year[15] - The adjusted EBITDA margin was 131% in Q3 2025, a decrease of 40 bps year-over-year[15] - Free Cash Flow for Q3 2025 was $(4) million[32] - The company is raising its 2025 revenue guidance to $5970 - $6030 million, representing a 14% to 15% year-over-year increase[21] - The company is raising its 2025 Free Cash Flow guidance to $170 - $190 million[21] Segment Performance - Engine Services revenue grew by 213% year-over-year in Q3 2025[34] - Component Repair Services revenue grew by 139% year-over-year in Q3 2025[39] - Component Repair Services achieved an adjusted EBITDA margin of 307% in Q3 2025, an increase of 430 bps year-over-year[39] Balance Sheet - The Net Debt to Adjusted EBITDA leverage ratio improved to 29x[50]

Financial Performance - 3Q25 revenue reached $60.2 million, exceeding the high-end of the guidance range of $56 million to $59 million[8] - Adjusted EBITDA for 3Q25 was $4.8 million, also surpassing the high-end of the guidance range of $(4) million to $(2) million[8] - Recurring revenue accounted for 92% of total revenue in 3Q25, amounting to $55.1 million[8] - The company anticipates adjusted EBITDA to exceed Capex in FY25[8] Customer Metrics - The average revenue per customer (ARPC) increased to $665,000 in 3Q25[16] - Net revenue retention rate for recurring revenue was 78% in 3Q25[16] - Remaining performance obligations stood at $197 million in 3Q25[16] Guidance - 4Q25 revenue is projected to be between $50.5 million and $55.5 million, representing a year-over-year decline of (31)% to (24)%[19] - Full year 2025 revenue is guided to be in the range of $235 million to $240 million, a year-over-year decrease of (25)% to (23)%[19] - Adjusted EBITDA for 4Q25 is expected to be between $(0.3) million and $4.7 million, with a margin of (0.6)% to 8.5%[19] - Full year 2025 adjusted EBITDA is projected to be between $7.5 million and $12.5 million, with a margin of 3.2% to 5.2%[19]

THIRD QUARTER 2025 BUSINESS UPDATE This communication contains "forward-looking statements" that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "would," "potential," "projects," "predicts," ...

Financial Performance - Q3 2025 revenue reached $123.3 million, a 21.6% year-over-year increase[16] - Q3 2025 gross margin improved to 37.6%, a 4.4 percentage point increase year-over-year[16] - Q3 2025 adjusted net profit was $11.9 million[18,50] - Q3 2025 adjusted EBITDA was $21.9 million[20,50] - The company ended the period with $143 million in cash, including restricted cash, a $33 million increase[59] Business Development and Strategy - The company established a partnership with Škoda Group to develop battery systems for rail applications, with the first prototype expected by the end of 2026[44] - The company is expanding its Huzhou facility with Phase 3.2, expected to provide an additional 2 GWh of capacity annually, with initial production anticipated in Q1 2026[28,33] - The company is focused on product innovation, market capture, and capacity expansion[23,24] Outlook - The company projects revenue growth of 18-25% for 2025, with revenue guidance of $450-475 million[63,64] - The company is targeting a gross margin range of 32%-35% for 2025[65] - The company anticipates over 50% year-over-year revenue growth in the Americas for 2025[67]

3Q 2025 Earnings Presentation November 2025 FORWARD- LOOKING STATEMENTS Statements made in this presentation regarding American Public Education, Inc. or its subsidiary institutions ("APEI" or the "Company") that are not historical facts are forward-looking statements based on current expectations, assumptions, estimates and projections about APEI and the industry. In some cases, forward looking statements can be identified by words such as "anticipate," "believe," "seek," "could," "estimate," "expect," "in ...